RNA-sequencing–based subtyping of pancreatic ductal adenocarcinoma (PDAC) has been reported by multiple research groups, each using different methodologies and patient cohorts. “Classical” and “basal-like” PDAC subtypes are associated with survival differences, with basal-like tumors associated with worse prognosis.
We amalgamated various PDAC subtyping tools to evaluate the potential of such tools to be reliable in clinical practice. Read more . . .